U.S. markets closed

AIkido Pharma Inc. (AIKI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.32+0.07 (+1.12%)
At close: 04:00PM EDT
6.22 -0.10 (-1.58%)
After hours: 05:18PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close6.25
Bid6.22 x 2200
Ask6.32 x 800
Day's Range6.18 - 6.47
52 Week Range4.30 - 16.66
Avg. Volume81,481
Market Cap33.196M
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)-1.85
Earnings DateNov 09, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMay 12, 1980
1y Target Est34.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AIKI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • AIkido Pharma Inc.
    Daily – Vickers Top Buyers & Sellers for 04/26/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • PR Newswire

    AIkido Pharma Confirms Receipt of Unsolicited Offer

    AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today confirms that on August 9, 2022, the Company received an unsolicited offer from Mr. Shalom Auerbach to acquire all of the Company's outstanding common stock for $8.00 per share in cash.

  • GlobeNewswire

    Investor Makes Proposal to Acquire AIkido Pharma for $8.00 Per Share in Cash

    Proposal for All-Cash Transaction Represents a 31% Premium to AIKI’s Most Recent Closing Price Urges the Board to Immediately Enter into Good Faith Discussions with the Investor and Work to Deliver a Meaningful Premium to AIKI’s Stockholders NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Shalom Auerbach, a significant stockholder of AIkido Pharma Inc. (NASDAQ: AIKI) (“AIKI” or the “Company”) beneficially owning approximately 3.8% of its common stock, today announced that he has sent a letter propos

  • PR Newswire

    AIkido Pharma, Inc. Hires Carlos Aldavero to Lead Financial Services Subsidiary

    Anthony Hayes, CEO of AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company"), announced the hiring of Carlos Aldavero as President of Dominari Financial, the recently formed financial services subsidiary of AIkido. Mr. Aldavero joins Dominari from Morgan Stanley where he was Associate Complex Manager overseeing one of the largest and most profitable business units at the venerable Wall St. firm.